Early Aspirin Discontinuation After Percutaneous Coronary Intervention in Acute Coronary Syndrome: A Systematic Review and Meta-analysis of Randomized Controlled Trials

This publication has 21 references indexed in Scilit:

• De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials
  The Lancet, 2024
• 2023 ESC Guidelines for the management of acute coronary syndromes
  European Heart Journal, 2023
• Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome
  JAMA Cardiology, 2022
• Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk
  New England Journal of Medicine, 2021
• Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome
  JAMA, 2020
• Ticagrelor with or without Aspirin in High-Risk Patients after PCI
  New England Journal of Medicine, 2019
• Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention
  JAMA, 2019
• Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
  The Lancet, 2018
• Predictors of Coronary Stent Thrombosis
  JACC, 2009
• Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study
  The Lancet, 2007